PHARMACY MARKET

Ionis and AstraZeneca close deal to develop and commercialize eplontersen

Ionis Pharmaceuticals, Inc. | December 30, 2021

Ionis Pharmaceuticals, Inc.  the leader in RNA-targeted therapies,  announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthyretin, or TTR protein, to treat ATTR, a systemic, progressive and fatal disease. It uses Ionis' advanced LIgand-Conjugated Antisense technology.

As previously announced, the companies will jointly develop and commercialize eplontersen in the U.S. AstraZeneca has an exclusive license for eplontersen outside the U.S., except certain countries in Latin America. Under the terms of the agreement, Ionis will receive a $200 million upfront payment, up to $485 million in development and approval milestones, and up to $2.9 billion in sales-related milestone payments. The collaboration includes territory-specific development, commercial and medical affairs cost-sharing provisions. Ionis is also eligible to earn royalties in the range of low double-digit to mid-20s percentage depending on region. Additional details about the agreement can be found in Ionis' Form 8-K filed with the Securities and Exchange Commission on Dec. 7, 2021.

About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.

Spotlight

In this fast-paced industry, you can rely on Taylor & Francis to provide access to the latest, high-impact content to guide critical work and drive new insights.

Spotlight

In this fast-paced industry, you can rely on Taylor & Francis to provide access to the latest, high-impact content to guide critical work and drive new insights.

Related News

Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Collaboration Agreement to Further Advance the Field of Molecular Imaging & Therapeutics

SOFIE Biosciences, Inc. | November 05, 2020

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to continue to grow production capacity, advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution within the U.S. "SOFIE is a beacon of innovation, and with Jubilant's deep experience, uncompromised quality and customer-centric operations, we will bring game-changing theranostic solutions to nuclear medicine," stated Sergio Calvo, President of Jubilant's Radiopharmaceuticals Division. "With this new relationship, SOFIE achieves another milestone in our innovation strategy," Philipp Czernin, SOFIE's Chief Revenue Officer, remarked. "By engaging a well-established industry partner such as Jubilant Radiopharma, SOFIE will leverage the combined market presence and astute organizational structure to deliver breakthrough compounds to the nuclear medicine community. With respective distribution capabilities and the highly complementary product portfolio of SPECT and PET radiopharmaceuticals, both companies are well poised to create a single-vendor opportunity in select geographies." As part of the agreement, Jubilant Radiopharma will invest US $25m into SOFIE Biosciences. This funding will help accelerate the readiness timelines for SOFIE's state-of-the-art Theranostics Center of Excellence Manufacturing Facility in Totowa, New Jersey, as well as advance the development of their Fibroblast Activation Protein Inhibitor (FAPI) program. Patrick Phelps, SOFIE's President and Chief Executive Officer stated, "Under this strategic partnership, SOFIE is excited to meet the growing need to manufacture highly specialized radiopharmaceuticals, as well as become the first theranostic production center for FAPI in the US. FAPI has received worldwide acclaim for its value as a key next-generation theranostic agent with the ability to greatly enhance the detection and treatment of a wide variety of oncology diseases, and we believe with Jubilant Radiopharma's investment and support, we can accelerate the development and commercialization of this exciting family of compounds." "This agreement is yet another demonstration of Jubilant Radiopharma's long term commitment to the global Nuclear Medicine community. Our teams are dedicated to bringing to market the next generation of breakthrough products and industry-leading services to healthcare providers across the globe as part of our mission of improving lives through Nuclear Medicine," stated Pramod Yadav, CEO Jubilant Pharma Limited. About SOFIE Biosciences, Inc SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine.

Read More

PHARMA TECH

CPhI partners with Informa Pharma Intelligence to present the 2021 Hybrid Edition of CPhI - P-MEC Expo in the National Capital Region ( NCR)

Informa Pharma Intelligence | November 26, 2021

Informa Pharma Intelligence, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 2021 hybrid edition of CPhI – P-MEC conducted by CPhI Conference. The Online Conference & Networking is being held between 15th to 30th Nov 2021, while the In-Person event is being held between 24th to 26th Nov 2021 at India Expo Centre– Greater Noida, Delhi. In a bid to stay afloat towards increasing contemporary demand towards high quality, low cost pharma solutions, CPhI & P_MEC India has curated a platform through this event for a gateway to latest trends and innovative solutions that the market has to offer. The event aims to build better pharma community engagements, network amongst the fraternity and source innovative solutions on-site from exhibitors who have footprints both domestically and globally, and covering the entire pharma supply chain - from APIs, machinery, technology, packaging, outsourcing, finished products and biopharmaceuticals. The industry is anticipated to have a steady growth trajectory and the event organised by CHhI India has focused on the key driving factors for the same. The expansion of medicine manufacturing pertaining to the evolving epidemiological profile of the country will be instrumental for India being the preferred drug manufacturing destination on a global scale. Additionally the event aims to encourage the development of the research-based pharma fraternity. "The Indian pharmaceutical industry has been growing at double digits year-on-year, and remains committed to not only providing solutions to the healthcare needs of the country, but also to the world. As the world is battling the pandemic at different levels, here in India, we remain committed to ramping up production capabilities of some key medicines across infectious and non-infectious diseases to ensure their availability and accessibility to the country and the world. The CPhI – P-MEC India show is the single location for all pharmaceutical and allied companies to get together and share insights, techniques and technology that will help meet these demands." Speaking at the sidelines of the CPhI – P-MEC India show, Mr Yogesh Mudras, Managing Director, Informa Markets in India As a part of the management team of the CPhI – P-MEC 2021 event, Mr Poornachandra Tejasvi, Senior Director, Emerging Markets, India, at Informa Pharma Intelligence said, "As a representative of the world's leading pharmaceutical business intelligence provider, its heart-warming to be a part of the CPhI – P-MEC event where we get to share meaningful insights drawn from real-time news, trends, market analysis, special reports, to key pharmaceutical companies in the country and the world. Globally we provide intelligence to over 10,000 customers and 3,000 of the top pharma, biotech and biosimilar companies with the collective support of more than 300 respected Business Intelligence subject matter analysts, editors, and thought leaders located across countries. The 2021 CPhI – P-MEC event will be a great opportunity to reconnect with the stakeholders of the pharmaceutical world and provide them with any form of data intelligence and analysis as needed." The Indian pharmaceutical market is growing at 15% annually, twice the world market growth rate. While its generics market is growing strong, it is also evolving into a cradle for new drugs. Therefore, with India being one of the strongest emerging markets in the global pharma industry, it presents great opportunities for all international pharmaceutical companies to explore, the platform by CPhI & P-MEC provides full access to the exhibitors to source new pharma solutions and find the right partners for your business with the ongoing hybrid expo showcasing the full drug development supply-chain from exporting, outsourcing, manufacturing, machinery, regulations, pricing, and market access to, packaging, labelling, and digitalization. The P-MEC event is the single destination in the country today for all things associated with the latest innovative pharma solutions that the world has to offer. The venue will also host the latest types of equipment associated with research and development and analytical solutions followed by cleanroom engineering design, certifications and the latest types of air purification solutions. The packaging technology on display will include a comprehensive range of glass, pouches, bottles, caps, tubes and plastic packages as well as printing and trademark solutions. CPhI India is a sister brand of CPhI Worldwide – A key event that all professionals from the international pharmaceutical and allied industries look forward to year on year. CPhI India and its co-located event, P-mec India, are the largest and most comprehensive pharmaceutical industry events in South Asia. This event is specifically important to the country as India is already labelled as the pharmacy of the world in addition to the vaccine manufacturing prowess showcased in 2019-2020. About Informa Pharma Intelligence Trusted by over 3,000 of the world's leading pharmaceutical, biotech, medical device companies, and CROs, the Pharma Intelligence suite of intelligence solutions, which include Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™, deliver vital, accurate, and timely intelligence and analysis about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. A global team of subject area experts track and analyse key diseases, clinical trials, drug approvals and R&D activities, to deliver data needed to make decisions and create real-world opportunities for growth. About CPhI Conferences The world's largest pharmaceutical exhibition, CPhI Worldwide represents every stage of the pharmaceutical supply chain - from ingredients and FDF, to machinery, packaging, outsourcing and biopharmaceuticals. Each year the CPhI brand unites more than 100,000 pharmaceutical professionals from all over the world through exhibitions, conferences and online communities. CPhI offers healthcare experts a chance to network, identify business opportunities and expand the global market through online and in-person interactions, with events in Europe, China, Korea, India, Japan, Southeast Asia and North America.

Read More

PHARMA TECH

SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases

SciNeuro Pharmaceuticals | October 26, 2021

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE) for neurodegenerative diseases for which there are currently no effective treatments. Both TDP-43 and APOE have human genetic evidence causal to ALS and Alzheimer’s disease. SciNeuro will have rights to develop and commercialize resulting product(s) within Greater China, and an option to expand such rights to become worldwide. “We are excited to be collaborating with Mabylon, a leading biotech company with deep expertise and capabilities for identification and characterization of native human antibodies with therapeutic potential. Their platform enables a deeper exploration of human immunology for therapeutic discovery Native human antibody-based approaches have proven successful for the treatment of infectious diseases including COVID-19. Discovery of auto-antibodies to treat other diseases has been more challenging, due in part to the availability of sufficiently large and high-quality sample collections. By working with companies such as Mabylon, possessing both proprietary antibody screening and cloning technology coupled with large, re-contactable patient sera repositories, we are in a strong position to test the hypothesis and exploit human immune responses for novel and differentiated therapeutic candidates for CNS diseases.” Dr. Min Li, Founder and CEO, SciNeuro Pharmaceuticals “Collaborating with SciNeuro and its R&D team allows full exploitation of Mabylon’s human antibody platform by seamlessly bringing our discovery research products forward to pivotal proof of concept. We are thrilled about this collaboration, which combines innovation in drug discovery with great expertise in drug development in the neurological disease area,” added Dr. Alcide Barberis, CEO, Mabylon. About Mabylon AG Mabylon AG is a leading Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat neurodegenerative diseases and allergies. Access to over 100,000 patients per year allows the discovery of extremely rare target-specific human antibodies, additionally providing information about the target’s human biology and safety profile.. About SciNeuro Pharmaceuticals SciNeuro Pharmaceuticals is a leading neuromedicine company focused on elevating the standard of care for patients suffering from neurological diseases. With R&D capabilities located in the major life sciences hubs of Shanghai, China and Rockville, Maryland, SciNeuro is establishing a robust CNS product pipeline through internal innoylon and SciNeuro will work together to discover and develop human auto-antibodies against targets of mutual interest with a goal to develop differentiated biologic therapeutics to treat neurological diseases.

Read More